An Open-label, Dose-finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Enterovirus A vaccine (Primary)
- Indications Enterovirus infections
- Focus Adverse reactions
- Sponsors Enimmune Corporation
- 02 Jun 2016 New trial record